---
layout: default
---

# Configurations

| UniProt Accession Number   | Reagent Type     | Target Name / Protein Biomarker   | Target Species   | Host Organism   | Isotype   | Clonality   | Vendor    |   Catalog Number | Conjugate   | RRID      | Availability   | Method        | Tissue Preservation               | Target Tissue                    | Tissue State   | Detergent         | Antigen Retrieval Conditions   | Dye Inactivation Conditions   | Recommend   | Agree                                                        | Disagree   | Contributor                                                  | Notes       |
|:---------------------------|:-----------------|:----------------------------------|:-----------------|:----------------|:----------|:------------|:----------|-----------------:|:------------|:----------|:---------------|:--------------|:----------------------------------|:---------------------------------|:---------------|:------------------|:-------------------------------|:------------------------------|:------------|:-------------------------------------------------------------|:-----------|:-------------------------------------------------------------|:------------|
| P06800                     | Primary Antibody | CD45                              | Mouse            | Rat             | IgG2b     | 30-F11      | BioLegend |           103124 | AF647       | AB_493533 | Stock          | IBEX2D Manual | 1:4 Cytofix/Cytoperm Fixed Frozen | Pancreatic Ductal Adenocarcinoma | Tumor          | 0.3% Triton-X-100 | NA                             | 1 mg/ml LiBH4 15 minutes      | Yes         | [0009-0007-0646-7946](https://orcid.org/0009-0007-0646-7946) | NA         | [0009-0007-0646-7946](https://orcid.org/0009-0007-0646-7946) | [1](#notes) |

# Publications



# Additional Notes

<a name="notes"></a>
1. The AF647 conjugate (103124) and AF532 conjugate (58-0451-82) label immune cells in the tumor microenvironment. Both conjugates are recommended for investigating immune infiltration in pancreatic tumors.